CTi Biopharma Corp Top Management

CTi Biopharma Management Team Effectiveness

The company has return on total asset (ROA) of (0.2858) % which means that it has lost $0.2858 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (10.1875) %, meaning that it created substantial loss on money invested by shareholders. CTi Biopharma's management efficiency ratios could be used to measure how well CTi Biopharma manages its routine affairs as well as how well it operates its assets and liabilities.

CTi Biopharma Workforce Comparison

The company has Profit Margin (PM) of (0.91) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.74) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.74.

CTi Biopharma Insider Trading

CTi Biopharma Notable Stakeholders

The success or failure of an entity such as CTi Biopharma Corp often depends on how effective the management is. CTi Biopharma management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of CTi management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the CTi management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.

The data published in CTi Biopharma's official financial statements usually reflect CTi Biopharma's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of CTi Biopharma Corp. For example, before you start analyzing numbers published by CTi accountants, it's critical to develop an understanding of what CTi Biopharma's liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.

Please note, the presentation of CTi Biopharma's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, CTi Biopharma's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in CTi Biopharma's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of CTi Biopharma Corp. Please utilize our Beneish M Score to check the likelihood of CTi Biopharma's management manipulating its earnings.

Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.

If you are still planning to invest in CTi Biopharma Corp check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the CTi Biopharma's history and understand the potential risks before investing.